|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/14/21 India Globalization Capital, Inc. 10-K 3/31/21 94:6.1M Federal Filings, LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 801K
2: EX-21.1 Subsidiaries List HTML 31K
3: EX-23.1 Consent of Expert or Counsel HTML 24K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
14: R1 Document And Entity Information HTML 59K
15: R2 Consolidated Balance Sheets HTML 149K
16: R3 Consolidated Balance Sheets (Parentheticals) HTML 42K
17: R4 Consolidated Statements of Operations and HTML 91K
Comprehensive Loss
18: R5 Consolidated Statement of Stockholders? Equity HTML 75K
19: R6 Consolidated Statements of Cash Flows HTML 112K
20: R7 Nature of Operations and Management's Plans HTML 32K
21: R8 Significant Accounting Policies HTML 63K
22: R9 Inventory HTML 37K
23: R10 Deposits and Advances HTML 37K
24: R11 Intangible Assets HTML 52K
25: R12 Property, Plant and Equipment HTML 54K
26: R13 Investments in Non-Marketable Securities HTML 41K
27: R14 Claims and Advances HTML 37K
28: R15 Leases HTML 65K
29: R16 Accrued Liabilities and Others HTML 36K
30: R17 Loans and Other Liabilities HTML 38K
31: R18 Commitments and Contingency HTML 30K
32: R19 Securities HTML 33K
33: R20 Stock-Based Compensation HTML 63K
34: R21 Fair Value of Financial Instruments HTML 81K
35: R22 Income Taxes HTML 85K
36: R23 Revenue Recognition HTML 47K
37: R24 Segment Information HTML 109K
38: R25 Subsequent Events HTML 28K
39: R26 Accounting Policies, by Policy (Policies) HTML 118K
40: R27 Inventory (Tables) HTML 36K
41: R28 Deposits and Advances (Tables) HTML 37K
42: R29 Intangible Assets (Tables) HTML 53K
43: R30 Property, Plant and Equipment (Tables) HTML 54K
44: R31 Investments in Non-Marketable Securities (Tables) HTML 40K
45: R32 Claims and Advances (Tables) HTML 37K
46: R33 Leases (Tables) HTML 70K
47: R34 Accrued Liabilities and Others (Tables) HTML 36K
48: R35 Loans and Other Liabilities (Tables) HTML 33K
49: R36 Stock-Based Compensation (Tables) HTML 67K
50: R37 Fair Value of Financial Instruments (Tables) HTML 79K
51: R38 Income Taxes (Tables) HTML 86K
52: R39 Revenue Recognition (Tables) HTML 42K
53: R40 Segment Information (Tables) HTML 108K
54: R41 Significant Accounting Policies (Details) HTML 43K
55: R42 Inventory (Details) HTML 29K
56: R43 Inventory (Details) - Schedule of Inventory, HTML 33K
Current
57: R44 Deposits and Advances (Details) HTML 26K
58: R45 Deposits and Advances (Details) - Deferred Costs, HTML 36K
Capitalized, Prepaid, and Other Assets Disclosure
59: R46 Intangible Assets (Details) HTML 32K
60: R47 Intangible Assets (Details) - Schedule of HTML 46K
Intangible Assets And Goodwill
61: R48 Intangible Assets (Details) - Schedule of HTML 36K
Finite-Lived Intangible Assets, Future
Amortization Expense
62: R49 Property, Plant and Equipment (Details) HTML 27K
63: R50 Property, Plant and Equipment (Details) - HTML 61K
Property, Plant and Equipment
64: R51 Investments in Non-Marketable Securities (Details) HTML 32K
65: R52 Investments in Non-Marketable Securities (Details) HTML 35K
- Schedule of Investments
66: R53 Claims and Advances (Details) HTML 29K
67: R54 Claims and Advances (Details) - Schedule of Other HTML 33K
Assets, Noncurrent
68: R55 Leases (Details) HTML 34K
69: R56 Leases (Details) - Lease, Cost HTML 31K
70: R57 Leases (Details) - Lessee, Operating Lease, HTML 41K
Disclosure
71: R58 Leases (Details) - Lessee, Operating Lease, HTML 40K
Liability, Maturity
72: R59 Accrued Liabilities and Others (Details) HTML 29K
73: R60 Accrued Liabilities and Others (Details) - HTML 35K
Schedule of Accounts Payable and Accrued
Liabilities
74: R61 Loans and Other Liabilities (Details) HTML 59K
75: R62 Loans and Other Liabilities (Details) - Schedule HTML 28K
of Loans and Other Liabilities
76: R63 Commitments and Contingency (Details) HTML 30K
77: R64 Securities (Details) HTML 47K
78: R65 Stock-Based Compensation (Details) HTML 52K
79: R66 Stock-Based Compensation (Details) - Schedule of HTML 37K
Share-based Payment Award, Stock Options,
Valuation Assumptions
80: R67 Stock-Based Compensation (Details) - Nonvested HTML 44K
Restricted Stock Shares Activity
81: R68 Stock-Based Compensation (Details) - Share-based HTML 45K
Payment Arrangement, Option, Activity
82: R69 FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - HTML 48K
Schedule of Fair Value, Assets and Liabilities
Measured on Recurring Basis
83: R70 INCOME TAXES (Details) - Schedule of Effective HTML 46K
Income Tax Rate Reconciliation
84: R71 Income Taxes (Details) - Schedule of Components of HTML 38K
Income Tax Expense (Benefit)
85: R72 Income Taxes (Details) - Summary of Operating Loss HTML 67K
Carryforwards
86: R73 REVENUE RECOGNITION (Details) - Disaggregation of HTML 48K
Revenue
87: R74 Segment Information (Details) HTML 29K
88: R75 Segment Information (Details) - Revenue from HTML 40K
External Customers by Products and Services
89: R76 Segment Information (Details) - Revenue from HTML 43K
External Customers by Geographic Areas
90: R77 Segment Information (Details) - Schedule of HTML 54K
Revenue from External Customers and Long-Lived
Assets, by Geographical Areas
91: R78 Subsequent Events (Details) HTML 28K
93: XML IDEA XML File -- Filing Summary XML 173K
92: EXCEL IDEA Workbook of Financial Reports XLSX 105K
8: EX-101.INS XBRL Instance -- igc-20210331 XML 1.30M
10: EX-101.CAL XBRL Calculations -- igc-20210331_cal XML 154K
11: EX-101.DEF XBRL Definitions -- igc-20210331_def XML 676K
12: EX-101.LAB XBRL Labels -- igc-20210331_lab XML 1.22M
13: EX-101.PRE XBRL Presentations -- igc-20210331_pre XML 676K
9: EX-101.SCH XBRL Schema -- igc-20210331 XSD 187K
94: ZIP XBRL Zipped Folder -- 0001185185-21-000802-xbrl Zip 165K
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)
(SECTION 302 CERTIFICATION)
I, Ram Mukunda, certify that:
|
1. |
I have reviewed this annual report on Form 10-K of India Globalization Capital, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d. |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: June 14, 2021 |
By: |
/s/ Ram Mukunda |
||
|
President and Chief Executive Officer (Principal Executive Officer) |
||||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 6/14/21 | |||
| For Period end: | 3/31/21 | 5, 5/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/23/21 IGC Pharma, Inc. S-8 12/23/21 5:335K Federal Filings, LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/22/21 IGC Pharma, Inc. POS AM 4:206K Federal Filings, LLC/FA 1/13/21 IGC Pharma, Inc. 8-K:1,9 1/13/21 3:285K Federal Filings, LLC/FA 7/13/20 IGC Pharma, Inc. 10-K 3/31/20 106:6.9M Federal Filings, LLC/FA 6/14/19 IGC Pharma, Inc. 10-K 3/31/19 92:5.5M Federal Filings, LLC/FA 10/02/18 IGC Pharma, Inc. 424B5 1:432K Federal Filings, LLC/FA 10/10/17 IGC Pharma, Inc. DEF 14A 11/08/17 2:651K Federal Filings, LLC/FA 6/12/17 IGC Pharma, Inc. 8-K:8,9 6/12/17 2:35K Federal Filings, LLC/FA 8/06/12 India Globalization Capital, Inc. 8-K:5,9 8/01/12 2:63K Federal Filings, LLC/FA |